MDM2 SNP 309 and p 53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation

Radiotherapy and Oncology

Volumn 87, Issue 2, 2008, Pages 243-252

  Tu, Hsi Feng ^a   Chen, Hong Wen ^b   Kao, Shou Yen ^a   Lin, Shu Chun ^a   Liu, Chung Ji ^a,b,d   Chang, Kuo Wei ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Carcinoma; MDM2; Oral cavity; p 53; Polymorphism; Radiotherapy

Indexed keywords

ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SUSCEPTIBILITY; CELL DEATH; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH DISEASE; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ARECA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CODON; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43049157990     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.03.018     Document Type: Article

References (49)

1. Cahilly-Snyder L., Yang-Feng T., Francke U., and George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13 (1987) 235-244
2. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
3. Chen J., Marechal V., and Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13 (1993) 4107-4114
4. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., and Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275 (2000) 8945-8951
5. Barak Y., Gottlieb E., Juven-Gershon T., and Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8 (1994) 1739-1749
6. Jones S.N., Ansari-Lari M.A., Hancock A.R., et al. Genomic organization of the mouse double minute 2 gene. Gene 175 (1996) 209-213
7. Juven T., Barak Y., Zauberman A., George D.L., and Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8 (1993) 3411-3416
8. Zauberman A., Flusberg D., Haupt Y., Barak Y., and Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23 (1995) 2584-2592
9. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
10. Bond G.L., Hu W., and Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65 (2005) 5481-5484
11. Ma H., Hu Z., Zhai X., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett (2005)
12. Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., et al. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42 (2005) 694-698
13. Wilkening S., Bermejo J.L., Burwinkel B., et al. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66 (2006) 646-648
14. Pine S.R., Mechanic L.E., Bowman E.D., et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15 (2006) 1559-1561
15. Campbell I.G., Eccles D.M., and Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240 (2006) 195-197
16. Dong M., Ma G., Tu W., Guo K.J., Tian Y.L., and Dong Y.T. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 11 (2005) 2162-2165
17. Millikan R.C., Heard K., Winkel S., et al. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15 (2006) 175-177
18. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
19. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
20. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
21. Wegman P., Stal O., Askmalm M.S., Nordenskjold B., Rutqvist L.E., and Wingren S. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 16 (2006) 347-351
22. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 79 (2003) 927-941
23. Lu S.Y., Chang K.W., Liu C.J., et al. Ripe areca nut extract induces G1 phase arrests and senescence-associated phenotypes in normal human oral keratinocyte. Carcinogenesis 27 (2006) 1273-1284
24. Huang S.P., Wu W.J., Chang W.S., et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 2217-2224
25. Twu C.W., Jiang R.S., Shu C.H., and Lin J.C. Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan. J Form Med Assoc 105 (2006) 99-104
26. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 (1999) 129-134
27. Bartel F., Schulz J., Bohnke A., et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117 (2005) 469-475
28. Giordana M.T., Duo D., Gasverde S., et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro-Oncol 4 (2002) 115-122
29. Haitel A., Wiener H.G., Baethge U., Marberger M., and Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 6 (2000) 1840-1844
30. Patterson H., Gill S., Fisher C., et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69 (1994) 1052-1058
31. Polsky D., Melzer K., Hazan C., et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 94 (2002) 1803-1806
32. Ranuncolo S.M., Varela M., Morandi A., et al. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J Neurooncol 68 (2004) 113-121
33. Lo W.L., Kao S.Y., Chi L.Y., Wong Y.K., and Chang R.C. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg 61 (2003) 751-758
34. Ikeguchi M., Ueda T., Fukuda K., Yamaguchi K., Tsujitani S., and Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 25 (2002) 454-459
35. Cao C., Shinohara E.T., Niermann K.J., et al. Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer. Mol Cancer Ther 4 (2005) 1137-1145
36. Cao C., Shinohara E.T., Subhawong T.K., et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 5 (2006) 411-417
37. Gadducci A., Di Cristofano C., Zavaglia M., et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 26 (2006) 687-693
38. Marin M.C., Jost C.A., Brooks L.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25 (2000) 47-54
39. Lee J.M., Shun C.T., Wu M.T., et al. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 594 (2006) 181-188
40. Bergamaschi D., Gasco M., Hiller L., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402
41. Agarwal S., Mathur M., Srivastava A., and Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol 35 (1999) 209-216
42. El-Kenawy Ael M., El-Kott A.F., and Khalil A.M. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder. Int J Biol Markers 18 (2003) 284-289
43. Shwe M., Chiguchi G., Yamada S., et al. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas. J Med Dent Sci 48 (2001) 113-119
44. Tuna B., Yorukoglu K., Tuzel E., Guray M., Mungan U., and Kirkali Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 199 (2003) 323-328
45. Xue Q., Sano T., Kashiwabara K., Oyama T., and Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung. Jpn J Cancer Res 92 (2001) 285-292
46. Huang J.S., Ho T.J., Chiang C.P., Kok S.H., Kuo Y.S., and Kuo M.Y. MDM2 expression in areca quid chewing-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 30 (2001) 53-58
47. Khor L.Y., Desilvio M., Al-Saleem T., et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 104 (2005) 962-967
48. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol/Hematol 54 (2005) 171-196
49. Carles J., Monzo M., Amat M., et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1022-1030